Kidswell Bio Corporation (4584)
Market cap
¥12B
P/E ratio
KidsWell Bio develops biosimilar drugs and regenerative medicine treatments using SQ-SHED stem cells from baby teeth for pharmaceutical partners and rare disease patients.
| Period End | Net income (Million JPY) | YoY (%) |
|---|---|---|
| Mar 31, 2025 | -21 | -98.51% |
| Mar 31, 2024 | -1,422 | +116.31% |
| Mar 31, 2023 | -657 | +22.83% |
| Mar 31, 2022 | -535 | -46.55% |
| Mar 31, 2021 | -1,001 | -86.31% |
| Mar 31, 2020 | -7,316 | +754.43% |
| Mar 31, 2019 | -856 | -5.34% |
| Mar 31, 2018 | -905 | -26.13% |
| Mar 31, 2017 | -1,225 | +55.46% |
| Mar 31, 2016 | -788 | -0.57% |
| Mar 31, 2015 | -792 | +52.55% |
| Mar 31, 2014 | -519 | +37.73% |
| Mar 31, 2013 | -377 | +17.46% |
| Mar 31, 2012 | -321 |